Accéder au contenu
Merck

[Pathomorphism of rectal cancer during neoadjuvant chemoradiotherapy].

Arkhiv patologii (2014-03-15)
A Iu Abrosimov, B A Berdov, D V Erygin, L M Kondrashova, E F Lushnikov, A A Nevol'skikh
RÉSUMÉ

The pathomorphism of rectal cancer (RC) was studied in 99 patients who received neoadjuvant chemoradiotherapy using two drugs (5-fluorouracil and xeloda). A morphological study indicated the qualitatively similar manifestations of pathomorphism (tumor necrosis, inflammation, and sclerosis) which were more pronounced in the use of xeloda. Three degrees of the pathomorphism of RC have been identified: the tumor was unchanged, changed, and undetectable.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Capecitabine, ≥98% (HPLC)
Capecitabine, European Pharmacopoeia (EP) Reference Standard